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Although positron emission tomography (PET) and the aromatic L-amino acid decarboxylase (AADC) tracer 6-[18F]ﬂ  uoro-L-m-tyrosine 
(FMT) has been used to assess the integrity of the presynaptic dopamine system in the brain, relatively little has been published in terms 
of brain FMT uptake values especially for normal human subjects. Twelve normal volunteer subjects were scanned using PET and FMT 
to determine the range of normal striatal uptake values using Patlak graphical analysis. For comparison, seven adult rhesus monkeys 
were studied and the data analyzed in the same way. A subset of monkeys that were treated with a unilateral intracarotid artery infusion 
of the dopamine neurotoxin MPTP showed an 87% decrease in striatal FMT uptake. These ﬁ  ndings support the use of PET and FMT to 
image AADC distribution in both normal and diseased brains using Patlak graphical analysis and tissue input functions.
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INTRODUCTION
Positron emission tomography (PET) has been used extensively to 
study the activity of aromatic L-amino acid decarboxylase (AADC) in 
the brains of both human and nonhuman primates. The most widely 
used tracer for the assessment of AADC continues to be 6-[18F]ﬂ  uoro-L-
DOPA (FDOPA). While FDOPA is well validated as a dopaminergic tracer 
(Eidelberg et al., 1994; Pate et al., 1993; Vingerhoets et al., 1994), it 
has the disadvantage of being subject to peripheral metabolism by cat-
echol-O-methyltransferase (COMT). The resulting methylated metabo-
lites are transported across the blood-brain barrier by the large neutral 
amino acid transporter and contribute to the PET signal in the brain 
thereby degrading the signal to noise ratio and complicating kinetic 
modeling (Doudet et al., 1991; Wahl et al., 1994). An alternative AADC 
tracer, 6-[18F]ﬂ  uoro-L-m-tyrosine (FMT), is not subject to O-methylation 
resulting in better quality images with higher signal to noise and more 
straightforward kinetics (DeJesus et  al., 1997; Jordan et  al., 1997; 
Nahmias et al., 1995). We have used FMT extensively in the study of 
both normal and parkinsonian monkeys treated with the dopamine 
neurotoxin MPTP (Bankiewicz et  al., 2006a,b; Eberling et  al., 1997, 
1998a, 2000, 2003; Forsayeth et al., 2006; Jordan et al., 1997) and 
have recently begun PET-FMT studies in normal human subjects and 
patients with Parkinson’s disease (PD). Although FMT has been used 
previously by other groups, little has been published about its use in 
normal human subjects. The current report provides normative values 
for humans and monkeys. We also compared FMT uptake in monkeys 
before and after MPTP treatment as an animal model of PD in order to 
evaluate the use of this approach in an established disease model.
MATERIALS AND METHODS
Human studies
Twelve volunteers, 9 males and 3 females, between the ages of 41 
and 58 were recruited by advertisement. All of the subjects were in 
good health, had no history of alcohol or drug abuse, and had not been 
treated for depression or any other neurological or psychiatric condition. 
Informed consent was obtained from the subjects after the nature of the 
experimental procedures was explained. All procedures were in accord-
ance with the ethical standards of the institutional committee on human 
experimentation.
PET studies were performed on a Siemens ECAT EXACT HR PET scan-
ner in 2D acquisition mode. FMT was synthesized using a semi-remote 
chemical synthesis apparatus (O’Neil and VanBrocklin, 1995) by a modi-
ﬁ  cation of a previously described procedure (Namavari et al., 1993). All 
subjects were studied approximately 60–90 minutes following an oral 
dose of 2.5 mg/kg of carbidopa. Subjects were positioned on the scan-
ner bed and a thermoplastic mask was used to gently restrain the head. 
Prior to the emission scan a 10 minute transmission scan was obtained 
for attenuation correction.  Subsequently, approximately 3–5  mCi of 
FMT was be injected as a bolus in an antecubital vein and a dynamic 
acquisition sequence was obtained: 12  × 5,  6 × 10,  4 × 30,  6 × 60, 
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10 × 300 seconds. All procedures were performed in accordance with 
the National Institutes of Health guidelines and approved by the Human 
Subjects Quality Assurance Committee at the Lawrence Berkeley National 
Laboratory and the Committee for Protection of Human Subjects at the 
University of California at Berkeley.
Monkey studies
Seven adult rhesus macaques (mean age 5.14 ± 3.00) were studied on 
the same PET scanner. Animals were anesthetized with an i.m. injec-
tion of ketamine (15 mg/kg), intubated and placed on methoxyﬂ  urane 
  anesthesia. All animals were pretreated with an i.m. injection of ben-
zerazide (2  mg  kg), a peripheral decarboxylase inhibitor, 30  minutes 
before imaging. The animals were placed in a stereotaxic frame and 
positioned in the PET scanner. Images were obtained in the coronal plane. 
Transmission and emission data were collected in the same manner as 
the human studies but the emission scan lasted for 90 minutes. Since the 
human emission data were acquired for 60 minutes, only the ﬁ  rst 60 min-
utes of the monkey emission data were used in the data analysis. A 10–
15 mCi dose of FMT was injected simultaneously with the beginning of 
the emission scan. Five of the monkeys were studied in the same manner 
approximately 4 weeks after the unilateral intracarotid artery (ICA) infu-
sion of MPTP as previously described in detail (Bankiewicz et al., 1986; 
Jordan et al., 1997). This results in a near complete unilateral lesion of 
the nigrostriatal pathway on the side of infusion and a hemiparkinsonian 
syndrome on the side contralateral to infusion. All procedures were in 
accordance with the National Institutes of Health guidelines and approved 
by the Animal Welfare and Research Committee at the Lawrence Berkeley 
National Laboratory.
Data analysis
Data were reconstructed using an ordered subset expectation maximi-
zation (OSEM) algorithm with weighted attenuation, an image size of 
256 × 256, and 6 iterations with 16 subsets. A Gaussian ﬁ  lter with 6-mm 
FWHM was applied, with a scatter correction.
PET data were quantiﬁ  ed using a multiple time graphical analysis 
(“Patlak plot”). FMT data are amenable to this approach because FMT 
is an irreversibly bound tracer reaching steady state relatively quickly. 
These features, identical to those of FDOPA, deﬁ  ne suitability for graphi-
cal analysis for an irreversible tracer as described by Patlak (Patlak and 
Blasberg, 1985) and previous studies have demonstrated the appropri-
ateness of the Patlak model for the analysis of FMT data (Doudet et al., 
1999; Jordan et al., 1997). FMT uptake can be quantiﬁ  ed by Ki, which 
is the slope of linear ﬁ  tting between two time-activity curves: the time-
activity curve of a region of interest (ROI), in this case the striatum, and 
the time-activity curve of the blood input function (Patlak and Blasberg, 
1985). The blood activity curve can be replaced by the time-activity 
curve of a reference region in which the tracer is nonspeciﬁ  cally bound, 
in this case the cerebellum (averaged over right and left hemispheres) 
(Dhawan et al., 2002; Lammertsma and Hume, 1996). Examples of time-
activity curves for the striatum and cerebellum are shown in Figure 1. 
This approach has the obvious advantage of not requiring arterial blood 
sampling. Rather than Ki, FMT uptake in an ROI will be referred to as 
Ki
c to denote that the cerebellum was used as the reference region. Ki
c 
values were computed for the right and left striatum using ROIs drawn 
directly on the PET images. The Patlak model was ﬁ  t with dynamic data 
from each ROI between 24 and 60 minutes, when the regression is highly 
linear (r > 0.99). Averaged Ki
c values were calculated across all slices for 
each ROI. Thus, the conclusion of PET data reduction results in regional 
Ki values for each subject, as well as a Ki image in subject native space 
(see Figures 2 and 3).
Paired t-tests were used to compare Ki
c values in the monkeys before 
and after MPTP treatment.
The uptake and washout of FMT is shown for the cerebellum and the 
right and left striatum for one of the human subjects. Both uptake and 
Figure 1.  Time-activity curves.
Figure 2.  Human PET-FMT image.
Figure 3.  Monkey PET-FMT images.
washout are rapid for the cerebellum, indicating nonspeciﬁ  c binding. The 
striatum shows continuous uptake, plateauing at about 20 to 30 minutes 
and without evidence of washout indicating speciﬁ  c binding in regions 
rich in dopaminergic neurons.PET studies of dopamine function
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RESULTS
Figure 2 shows a parametric image of striatal FMT uptake (Ki) for a 
46-year-old human male.
The graphical method was implemented on a voxel-wise basis to 
produce calculated Ki images using a cerebellar reference input. This 
axial image at the level of the striatum demonstrates high levels of tracer 
uptake in the striatum as shown in a 46-year-old male subject.
Table 1 shows striatal FMT uptake (Ki
c) in normal humans and mon-
keys from this study as well as other published studies for comparison. 
Table 2 shows individual Ki
c values for the human subjects from this 
study in order to provide a comprehensive indication of the variability 
between subjects.
The striatal Ki
c values reported from our laboratory tended to be 
higher than those reported from other laboratories for both humans and 
monkeys. FMT uptake values were more variable when calculated using 
blood input functions as shown by the coefﬁ  cients of variation. Ki
c values 
decreased signiﬁ  cantly following unilateral MPTP treatment in monkeys 
(t = 13.46, p < 0.001), with reductions of 87% in the treated (left) hemi-
sphere. Figure 3 shows parametic images for a monkey studied before 
and after unilateral MPTP treatment.
Calculated  Ki images for a normal monkey (left) and the same 
  monkey after unilateral left intracarotid artery infusion of the neurotoxin 
MPTP. Both images are coronal slices taken at the level of the striatum. 
Left striatal FMT uptake was reduced more than 80% following MPTP 
treatment.
DISCUSSION
Our laboratory has extensive experience in FMT-PET imaging in nor-
mal and parkinsonian monkeys using several methods to analyze the 
data, including a 3-compartment tracer kinetic model, Patlak graphi-
cal analysis of tissue uptake, and a simple ratio approach (Eberling 
et al., 2004; Jordan et al., 1997). Our kinetic studies showed that 
brain radioactivity was in the form of 6-[18F]fluoro-m-tryramine 
(FMA) and 6-[18F]fluoro-3-hydroxyphenylacetic acid (FPAC), indicat-
ing a metabolic pathway consistent with decarboxylation of FMT to 
FMA and further metabolism by monoamine oxidase to FPAC. Results 
of primate studies using tracer kinetic modeling, Patlak graphical 
analysis, and simple striatum to cerebellum ratios were consistent 
with one another and showed substantial decarboxylation in regions 
of high dopamine content (caudate, putamen) (Eberling et al., 2004; 
Jordan et al., 1997). Here we report striatal FMT uptake in normal 
humans and monkeys using a multiple time graphical (Patlak) analy-
sis. In addition, we report similar reductions in striatal FMT uptake in 
MPTP-treated monkeys as previously reported using various analytic 
methods supporting the use of this approach in both normal and dis-
eased brains.
As shown in Table 1 striatal uptake values tend to be more variable 
when using arterial blood vs. tissue input functions. Doudet et al. (1999) 
Table 1.  FMT uptake values in normal humans and monkeys.
Species  N  Input function  Striatal uptake  COV  Comments  Reference
     Mean  ± SD  (%)
Human  12  Cerebellar ROI  0.021, 0.003  12  Normal subjects
         Age  40–58
Human  5  Occipital ROI  0.017, 0.002  12  Normal subjects  Nahmias et al., 1995
          Age 18–25 years
Human  6  Cerebellar ROI  0.018, NA  NA  Normal subjects  Mamo et al., 2204
          Mean age 26 ± 7
Human  4  Cerebellar ROI  0.019, 0.002  11  Age 25–54 years  Asselia et al., 2002
Human  4  Venous sinus ROI  0.019, 0.005  26  Age 25–54 years  Asselin et al., 2002
Monkey  7  Cerebellar ROI  0.022, 0.003  13  Mean age 5.14 ± 3
Monkey  6  Arterial blood  0.013, 0.003  23  Ages not available  Doudet et al., 1999
   (metabolic  corrected)
Monkey  6  Occipital ROI  0.013, 0.002  15  Ages not available  Doudet et al., 1999
Monkey  3  Occipital ROI  0.017, 0.0006  3.5  Ages 8, 9 and 30 years  Brown et al., 1999
     putamen  only
Monkey  5  Occipital ROI  0.012, 0.003  25  Age 3–13 years Partial  DeJesus et al., 2001
         volume  correction
Monkey  5  Occipital ROI  0.014, 0.002  14  Age 25–37 years   DeJesus et al., 2001
          Partial volume correction
Monkey  4  Arterial blood  0.023, 0.006  26  Age 5–10 years  Eberling et al., 2002
   (metabolic  corrected)       
Monkey  6  Arterial blood  0.018, 0.001  6  Age 22–27 years  Eberling et al., 2002
   (metabolic  corrected)       
Monkey  2  Cerebellar ROI  0.010, 0.00004  0.38  MicroPET Age 7 years  DeJessus et al., 2005
Table 2.  FMT uptake values for individual human subjects.
Subject Age Gender Striatal  uptake
1 53  M 0.019
2 41  M 0.022
3 46  M 0.019
4 55  M 0.025
5 41  M 0.021
6 52  M 0.017
7 50  M 0.023
8 58  M 0.019
9 40  F  0.017
10 46  M  0.023
11 50  F  0.024
12 49  F  0.021Eberling et al.
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reported more variability with arterial input functions than with tissue 
input functions (see Table 1). In fact, in general the studies that used 
image-derived tissue input functions, either the cerebellum or occipital 
cortex, showed less between subject variability than studies that used 
arterial input functions. Differences in uptake values between studies can 
likely be explained by differences in PET scanners and in the details of 
the analytic methods.
We considered measuring FMT values in cortical regions as well but 
opted not to because we were not conﬁ  dent that these measures are 
accurate. A number of studies (for review see Cropley et al. (2006)) have 
quantiﬁ  ed FDOPA uptake in cortical areas, often in association with cog-
nitive performance. However, the signal to noise ratio in the cortex is low 
for both FDOPA and FMT and the accuracy of cortical uptake values is 
uncertain (Cropley et al., 2006). We therefore chose to limit our analyses 
to the striatum.
The reductions in striatal FMT uptake we observed following unilat-
eral intracarotid artery infusions of MPTP are similar to what we have 
previously observed using arterial input functions and kinetic modeling 
(Eberling et al., 1998b; Jordan et al., 1997). Here, we report an 87% 
reduction in striatal FMT uptake using a Patlak analysis. Doudet et al. 
(1999) previously reported that both FMT and FDOPA showed similar 
reductions in striatal uptake following MPTP treatment in monkeys. 
In addition, they reported negligible differences when comparing stri-
atal FMT uptake values derived from arterial blood vs. occipital cortex 
input functions. Together, these ﬁ  ndings support the use of the graphi-
cal analytic approach using a tissue input function for FMT studies of 
normal and impaired dopamine function. This approach has the obvi-
ous advantage of avoiding arterial blood sampling which is technically 
more demanding, more invasive, and less practical, especially in clini-
cal settings.
While FDOPA is still the most commonly used tracer for the 
assessment of AADC, the quantification of FDOPA kinetics is signifi-
cantly affected by the influence of peripheral metabolites that cross 
the blood-brain barrier. FMT is not subject to peripheral methylation 
by COMT resulting in higher quality brain images. In the brain, while 
FDOPA is decarboxylated by AADC into 6-[18F]fluorodopamine (FDA), 
stored in vesicles, and subsequently metabolized by MAO and COMT, 
FMT is decarboxylated by AADC into FMA which has a low affin-
ity for the vesicular transporter (Endres et al., 1997) and is thereby 
simply further metabolized by MAO into FPAC and trapped in the 
tissue. Thus, as previously suggested by Doudet et al. (1999), FMT 
is a superior tracer for the assessment of AADC, while FDOPA is the 
tracer of choice for assessing dopamine metabolism and turnover. 
FMT may be the tracer of choice for routine clinical studies because 
the images have higher target to background ratios and therefore 
higher contrast.
In summary, we report striatal FMT uptake values in normal humans 
and monkeys using cerebellar input functions and Patlak graphical analy-
sis. Similar reductions in striatal FMT uptake were observed in MPTP 
treated monkeys using a Patlak graphical analysis to those reported 
previously using a arterial blood input functions and a kinetic modeling 
analytic approach (Eberling et al., 1998b; Jordan et al., 1997). These 
ﬁ  ndings support the use of FMT to image AADC distribution using Patlak 
graphical analysis and tissue input functions for assessing the integrity of 
presynaptic dopamine function in normal and diseased brains. Although 
absolute uptake rates may range considerably depending upon the scan-
ner, imaging protocol, and details of the analytic methods, relative rates 
appear to be similar when comparing studies done at different imaging 
centers.
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